

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10/758,155

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



Applicant:

McSwiggen et al.

Filing Date:

January 12, 2004

Group:

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
CR	*	09/226,044	07/12/01	Hoffman et al.			
	*	10/151,116	05/17/02	Matulic-Adamic et al.			
	*	10/201,394	08/13/01	Vargeese et al.			
	*	10/287,949	11/04/02	Pavco			
	*	10/306,747	11/27/02	Pavco			
	*	10/427,160	04/30/03	Vargeese et al.			
	*	10/438,493	05/15/03	Pavco et al.			
	*	10/444,853	05/23/03	McSwiggen et al.			
	*	10/664,668	09/18/03	McSwiggen et al.			
	*	10/664,767	09/16/03	McSwiggen et al.			
	*	10/665,255	09/16/03	McSwiggen et al.			
	*	10/665,951	09/18/03	McSwiggen et al.			
	*	10/670,011	09/23/03	McSwiggen et al.			
	*	10/693,059	10/23/03	McSwiggen et al.			
	*	10/712,633	11/13/03	McSwiggen et al.			
	*	10/720,448	11/24/03	McSwiggen et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEKHLEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10/758,155

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

January 12, 2004

Group:

✓	*	10/727,780	12/03/03	Vaish et al.			
	*	10/757,803	01/14/04	McSwiggen et al.			
	*	10/758,155	01/12/04	McSwiggen et al.			
	*	10/764,957	01/26/04	McSwiggen et al.			
	*	10/831,620	04/23/04	McSwiggen et al.			
	*	2001/0007666	07/12/01	Hoffman et al.			
	*	2002/0130430	09/19/02	Castor			
	*	2004/0037780	02/06/04	Parsons et al.			
	*	60/082,404	04/20/98	Thomson et al.			
	*	60/334,461	11/30/01	Pavco			
	*	60/358,580	02/20/02	Beigelman et al.			
	*	60/363,124	03/11/02	Beigelman et al.			
	*	60/386,782	06/06/02	Beigelman et al.			
	*	60/393,796	07/03/02	McSwiggen et al.			
	*	60/399,348	07/29/02	McSwiggen et al.			
	*	60/402,996	08/13/02	Usman et al.			
	*	60/406,784	08/29/02	Beigelman et al.			
	*	60/408,378	09/05/02	Beigelman et al.			
	*	60/409,293	09/09/02	Beigelman et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MCDONNELL BOEHREN
MULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10/758,155

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



Applicant:

McSwiggen et al.



Filing Date:



January 12, 2004

Group:

	*	60/440,129	01/15/03	Beigelman et al.			
	*	60/543,480	02/10/04	Jadhav et al.			

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	4,501,729	02/26/85	Boucher et al.			
	*	5,138,045	08/11/92	Cook et al.			
	*	5,214,136	05/25/93	Lin et al.			
	*	5,334,711	08/02/94	Sproat et al.			
	*	5,624,803	04/29/97	Noonberg et al.			
	*	5,627,053	05/06/97	Usman et al.			
	*	5,631,360	05/20/97	Usman et al.			
	*	5,670,633	09/23/97	Cook et al.			
	*	5,672,695	09/30/97	Eckstein et al.			
	*	5,716,824	02/10/98	Beigelman et al.			
	*	5,792,847	08/11/98	Buhr et al.			
	*	5,804,683	09/08/98	Usman et al.			
	*	5,814,620	09/29/98	Robinson et al.			

EXAMINER 	DATE CONSIDERED 
--	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10/758,155

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

January 12, 2004

Group:

*	5,831,071	11/03/98	Usman et al.			
*	5,854,038	12/29/98	Sullenger et al.			
*	5,889,136	03/30/99	Scaringe et al.			
*	5,898,031	04/27/99	Crooke			
*	5,902,880	05/11/99	Thompson			
*	5,998,203	12/07/99	Adamic et al.			
*	6,001,311	12/14/99	Brennen			
*	6,005,087	12/21/99	Cook et al.			
*	6,008,400	12/28/99	Scaringe et al.			
*	6,054,576	04/25/00	Bellon et al.			
*	6,107,094	08/22/00	Crooke			
*	6,111,086	08/29/00	Scaringe et al.			
*	6,117,657	09/12/00	Usman et al.			
*	6,146,886	11/14/00	Thompson et al.			
*	6,153,737	11/28/00	Manoharan et al.			
*	6,162,909	12/19/00	Bellon et al.			
*	6,180,613	01/30/01	Kaplitt et al.			
*	6,235,310	05/22/01	Wang et al.			
*	6,248,878	06/19/01	Matulic-Adamic et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHLEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10/758,155

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

January 12, 2004

Group:

•	6,300,074	10/09/01	Gold et al.			
•	6,303,773	10/16/01	Bellon et al.			
•	6,335,434	01/01/02	Guzaev et al.			
•	6,353,098	03/05/02	Usman et al.			
•	6,362,323	03/26/01	Usman et al.			
•	6,395,713	05/28/02	Beigelman et al.			
•	6,437,117	08/20/02	Usman et al.			
•	6,447,796	09/10/02	Vook et al.			
•	6,469,158	10/22/02	Usman et al.			
•	6,476,205	11/05/02	Buhr et al.			
•	6,506,559	01/14/03	Fire et al.			
•	6,528,631	03/04/03	Cook et al.			
•	6,565,885	05/20/03	Tarara et al.			
•	6,582,728	06/24/03	Platz et al.			
•	6,586,524	07/01/03	Sagara			
•	6,592,904	07/15/03	Platz et al.			

FOREIGN PATENT DOCUMENTS

Document	Date	Country	Class	Subclass	Translation
----------	------	---------	-------	----------	-------------

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MCDONNELL BOENKEN
MULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60608
TELEPHONE (312) 913-0001

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10758,155

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)


Applicant:

McSwiggen et al.

Filing Date:

January 12, 2004

Group:

		Number										
											Yes	No
	*	4037501	08/03/00	AU (Kreutzer et al.)								
	*	2,359,180	08/03/00	CA (Kreutzer et al.)								
	*	1144623	08/03/00	EP (Kreutzer et al.)								
	*	89/02439	03/23/89	WO (Arnold et al.)								
	*	90/14090	11/29/90	WO (Gillespie et al.)								
	*	91/03162	03/21/91	WO (Rossi et al.)								
	*	92/07065	04/30/92	WO (Eckstein et al.)								
	*	93/15187	08/05/93	WO (Usman et al.)								
	*	93/23569	11/25/93	WO (Draper et al.)								
	*	94/02595	02/03/94	WO (Sullivan et al.)								
	*	94/01550	01/20/94	WO (Agrawal et al.)								
	*	95/06731	03/09/95	WO (Usman et al.)								
	*	95/11910	05/04/95	WO (Dudycz et al.)								
	*	96/10390	04/11/96	WO (Ansell et al.)								
	*	96/10391	04/11/96	WO (Choi et al.)								
	*	96/10392	04/11/96	WO (Holland et al.)								
	*	96/18736	06/20/96	WO (Beigelman et al.)								
	*	97/26270	07/24/97	WO (Wincott et al.)								

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MCDONNELL BOEHMEN
MULBERT & BERCHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10/758,155

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

January 12, 2004

Group:

	*	98/13526	04/02/98	WO (Woolf et al.)				
	*	99/07409	02/18/99	WO (Deschamps de Paillette et al.)				
	*	99/14226	03/25/99	WO (Wengel et al.)				
	*	99/31262	06/24/99	WO (Barry et al.)				
	*	99/32619	07/01/99	WO (Fire et al.)				
	*	99/49029	09/30/99	WO (Graham et al.)				
	*	99/53050	10/21/99	WO (Waterhouse et al.)				
	*	99/54459	10/28/99	WO (Thompson et al.)				
	*	99/61631	12/02/99	WO (Heifetz et al.)				
	*	00/01846	01/13/00	WO (Plaetinck et al.)				
	*	00/44895	08/03/00	WO (Kreutzer et al.)				
	*	00/44914	08/03/00	WO (Li et al.)				
	*	00/49035	08/24/00	WO (Sheen)				
	*	00/53722	09/14/00	WO (O'Hare et al.)				
	*	00/63364	10/26/00	WO (Pachuk et al.)				
	*	00/66604	11/09/00	WO (Wengel et al.)				
	*	01/04313	01/18/01	WO (Satishchandran et al.)				
	*	01/29058	04/26/01	WO (Mello et al.)				
	*	01/36646	05/25/01	WO (Zernicka-Goetz et al.)				

EXAMINER	DATE CONSIDERED 2/15/06
----------	-------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHMEN
HILBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10/758,155

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

January 12, 2004

Group:

<i>JPR</i>	*	01/38551	05/31/01	WO (Grossniklaus et al.)				
	*	01/42443	06/14/01	WO (Churikov et al.)				
	*	01/49844	07/12/01	WO (Driscoll et al.)				
	*	01/53475	07/26/01	WO (Cogoni et al.)				
	*	01/68836	09/20/01	WO (Beach et al.)				
	*	01/70944	09/27/01	WO (Honer et al.)				
	*	01/70949	09/27/01	WO (Graham et al.)				
	*	01/72774	10/04/01	WO (Deak et al.)				
	*	01/75164	10/11/01	WO (Tuschl et al.)				
	*	01/92513	12/06/01	WO (Amdt et al.)				
	*	01/96584	12/20/01	WO (Mushegian et al.)				
	*	02/055692	07/18/02	WO (Kreutzer et al.)				
	*	02/055693	07/18/02	WO (Kreutzer et al.)				
	*	02/22636	03/21/02	WO (Bennett et al.)				
	*	02/38805	05/15/02	WO (Echeverri et al.)				
<i>W</i>	*	02/44321	06/06/02	WO (Tuschl et al.)				
	*	02/096927	12/05/02	WO (Payco)				
<i>W</i>	*	03/24420	03/27/03	WO (Alheim et al.)				
	*	03/46185	06/05/03	WO (Wang et al.)				

EXAMINER <i>W</i>	DATE CONSIDERED <i>2/16/05</i>
-------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MCDONNELL BOEMMEN
KILBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10/758,155

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

January 12, 2004

Group:

•	03/47518	06/12/03	WO (Wang et al.)				
•	PCT/US02/15876	05/20/02	Beigelman et al.				
•	PCT/US02/17674	05/29/02	WO (Pavco et al.)				
•	PCT/US03/05022	02/20/03	WO (McSwiggen et al.)				
•	PCT/US03/05028	02/20/03	McSwiggen et al.				
•	WO 03/070716	02/20/03	McSwiggen et al.				
•	PCT/US03/05346	02/20/03	McSwiggen et al.				
•	WO 03/064625	02/03/03	WO (Woolf et al.)				
•	WO 03/064626	02/03/03	WO (Woolf et al.)				
•	WO 03/030989	04/17/03	WO (Behar et al.)				
•	WO 03/043689	05/03/03	WO (Behar et al.)				
•	WO 04/013280	05/26/03	WO (Davidson et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

•	Adah et al., "Chemistry and Biochemistry of 2',5'-Oligoadenylate-Based Antisense Strategy," <i>Current Medicinal Chemistry</i> , 8, 1189-1212 (2001)
•	Aiello et al., "Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders," <i>The New England Journal of Medicine</i> 331(22):1480-1487 (1994)
•	Akhtar and Juliano, "Cellular Uptake and Intracellular Fate of AntiSense Oligonucleotides," <i>Trends Cell Biol.</i> 2:139-144 (1992)
•	Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <i>Nucleic Acids Research</i> 26:4910-4916 (1998)



EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al. Filing Date: January 12, 2004	
		Group:	

✓	* Allshire, "RNAi and Heterochromatin - A Hushed-up Affair," <i>Science</i> 297:1818-1819 (2002)
	* Andrews and Faller, "A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells," <i>Nucleic Acids Research</i> 19:2499 (1991)
	* Autiero et al., "Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1," <i>Nature Medicine</i> , 9:936-943 (2003)
	* Baenziger and Fiets, "Galactose and N-Acetylgalactosamine-Specific Endocytosis of Glycopeptides by Isolated Rat Hepatocytes," <i>Cell</i> 22:611-620 (1980)
	* Bahramian et al., "Transcriptional and Posttranscriptional Silencing of Rodent $\alpha 1(I)$ Collagen by a Homologous Transcriptionally Self-Silenced Transgene," <i>Molecular and Cellular Biology</i> , 274-283 (1999)
	* Bannai et al., "Effect of Injection of Antisense of Oligodeoxynucleotides of GAD Isozymes into Rat Ventromedial Hypothalamus on Food Intake and Locomotor Activity," <i>Brain Research</i> 784:305-315 (1998)
	* Bannai et al., "Water-absorbent Polymer as a Carrier for a Discrete Deposit of Antisense Oligodeoxynucleotides in the Central Nervous System," <i>Brain Research Protocols</i> 3:83-87 (1998)
	* Bass, "The short answer," <i>Nature</i> 411:428-429 (2001)
	* Bass, "Double-Stranded RNA as a Template for Gene Silencing," <i>Cell</i> , 101, 235-238 (2000)
	* Beaucage and Iyer, "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives," <i>Tetrahedron</i> 49:1925-1963 (1993)
	* Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <i>The Journal of Biological Chemistry</i> 270:25702-25708 (1995)
	* Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," <i>Nucleosides & Nucleotides</i> 16:951-954 (1997)
✓	* Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis," <i>Bioconjugate Chem.</i> 8:204-212 (1997)

EXAMINER 	DATE CONSIDERED 
---	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

Serial No.

02-742-N
(400/142)

10/758,155

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



Applicant:

McSwiggen et al.

Filing Date:

January 12, 2004

Group:

	*	Berkman et al., "Expression of the Vascular Permeability Factor/Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms," <i>The Journal of Clinical Investigation</i> , Inc. 91:153-159 (1993)
	*	Bernstein et al., "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference," <i>Nature</i> 409:363-366 (2001)
	*	Bettinger et al., "Size Reduction of Galactosylated PEI/DNA Complexes Improves Lectin-Mediated Gene Transfer into Hepatocytes," <i>Bioconjugate Chem.</i> , 10, 558-561 (1999)
	*	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>Journal of Pharmaceutical Sciences</i> 87:1308-1315 (1998)
	*	Boado, "Antisense drug delivery through the blood-brain barrier," <i>Advanced Drug Delivery Reviews</i> 15:73-107 (1995)
	*	Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," <i>Biotechnology and Bioengineering (Combinatorial Chemistry)</i> 61:33-45 (1998)
	*	Broadbudd et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," <i>J Neurosurg</i> 88:734-742 (1998)
	*	Brody and Gold, "Aptamers as therapeutic and diagnostic agents," <i>Reviews in Molecular Biotechnology</i> 74:5-13 (2000)
	*	Burger et al., "Experimental Corneal Neovascularization: Biomicroscopic, Angiographic, and Morphologic Correlation," <i>Cornea</i> 4:35-41 (1985/1986)
	*	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," <i>Biochemistry</i> 35:14090-14097 (1996) (volume no. mistakenly listed as 6)
	*	Burlina et al., "Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes," <i>Bioorganic & Medicinal Chemistry</i> 5:1999-2010 (1997)
	*	Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," <i>Methods in Enzymology</i> 211:3-19 (1992)



EXAMINER


DATE CONSIDERED

2/15/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.












FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: January 12, 2004	Group:

	* Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," <i>Nucleic Acids Research</i> 20:4581-4589 (1992)
	* Chiu et al., "siRNA function in RNAi: A chemical modification analysis," <i>RNA</i> , 9:1034-1048 (2003)
	* Choi et al., "Effect of Poly(ethylene glycol) Grafting on Polyethylenimine as a Gene Transfer Vector <i>in vitro</i> ," <i>Bull. Korean Chem. Soc.</i> , 22, 46-52 (2001)
	* Chowrira et al., "In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," <i>J. Biol. Chem.</i> 269:25856-25864 (1994)
	* Clark and Yoria, "Ophthalmic Drug Discovery," <i>Nature</i> , 2, 448-459 (2003)
	* Clemens et al., "The Double-Stranded RNA-Dependent Protein Kinase PKR: Structure and Function," <i>J. Interferon & Cytokine Res.</i> , 17, 503-524 (1997)
	* Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," <i>J. Am. Chem. Soc.</i> 113:6324-6326 (1991)
	* Connolly et al., "Binding and Endocytosis of Cluster Glycosides by Rabbit Hepatocytes," <i>The Journ. of Biol. Chem.</i> 257:939-945 (1982)
	* Conry et al., "Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration," <i>Clinical Cancer Research</i> 5:2330-2337 (1999)
	* Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," <i>Trends In Genetics</i> 12:510-515 (1996)
	* Detmar et al., "Overexpression of Vascular Permeability Factor/Vascular Endothelial Growth Factor and its Receptors in Psoriasis," <i>J. Exp. Med.</i> 180:1141-1146 (1994)
	* Diebold et al., "Mannose Polyethylenimine Conjugates for Targeted DNA Delivery into Dendritic Cells," <i>The Journal of Biological Chemistry</i> , 274, 19087-19094 (1999)

EXAMINER 	DATE CONSIDERED 1/15/06
---	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: January 12, 2004	Group:

	Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," <i>Journal of Virology</i> 66:1432-1441 (1992)
	Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <i>Nucleic Acids Research</i> 18:6353-6359 (1990) [sometimes referred to as Seela and Kaiser]
	Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <i>Biopolymers</i> 48:39-55 (1998)
	Economides et al., Cytokine traps: multi-component, high-affinity blockers of cytokine action," <i>Nature Medicine</i> , 9, 1, 47-52 (2003)
	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> 411:494-498 (2001)
	Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in Drosophila Melanogaster Embryo Lysate," <i>The EMBO Journal</i> 20:6877-6888 (2001)
	Elbashir et al., "RNA Interference is Mediated by 21- and 22-Nucleotide RNAs," <i>Genes and Development</i> 15:188-200 (2001)
	Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in <i>Delivery Strategies for Antisense Oligonucleotide Therapeutics</i> , edited by Akhtar, CRC Press, pp. 17-220 (1995)
	Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," <i>Proc. Natl. Acad. Sci. USA</i> 87:6743-6747 (1990)
	Emerich et al., "Biocompatibility of Poly.(DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <i>Cell Transplantation</i> 8:47-58 (1999)
	Epa et al., "Downregulation of the p75 Neurotrophin Receptor in Tissue Culture and <i>In Vivo</i> , Using β -Cyclodextrin-Adamantane-Oligonucleotide Conjugates," <i>Antisense Nuc. Acid Drug Dev.</i> , 10:469-478 (2000)

EXAMINER		DATE CONSIDERED	
----------	---	-----------------	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10/758,155

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



Applicant:



McSwiggen et al.

Filing Date:

January 12, 2004

Group:

	*	Erbacher et al., "Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI), <i>The Journal of Gene Medicine</i> , 1, 210-222 (1999) [sometimes incorrectly cited as pages 1-18]
	*	Fava et al., "Vascular Permeability Factor/Endothelial Growth Factor (VPF/VEGF): Accumulation and Expression in Human Synovial Fluids and Rheumatoid Synovial Tissue," <i>J. Exp. Med.</i> 180:341-346 (1994)
	*	Ferentz and Verdine, "Disulfied Cross-Linked Oligonucleotides," <i>J. Am. Chem. Soc.</i> 113:4000-4002 (1991)
	*	Filleur et al., "siRNA-mediated Inhibition of Vascular Endothelial Growth Factor Severely Limits Tumor Resistance to Antiangiogenic Thrombospondin-1 and Slows Tumor Vascularization and Growth," <i>Cancer Research</i> , 63, 3919-3922 (2003)
	*	Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <i>Nature</i> 391:806-811(1998)
	*	Fire, "RNA-triggered Gene Silencing," <i>TIG</i> 15:358-363(1999)
	*	Folkman et al., "Long-term Culture of Capillary Endothelial Cells," <i>Proc. Natl. Acad. Sci. USA</i> 76:5217-5221 (1979)
	*	Folkman, Judah, "Tumor Angiogenesis," <i>Advances in Cancer Research</i> 43:175-203 (1985)
	*	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <i>Proc. Natl. Acad. Sci. USA</i> 83:9373-9377 (1986) [sometimes referred to as Frier]
	*	Furgeson et al., "Modified Linear Polyethylenimine—Cholesterol Conjugates for DNA Complexation," <i>Bioconjugate Chem.</i> , 14, 840-847 (2003)
	*	Futami et al., "Induction fo apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2," <i>Nucleic Acids Research Supplement</i> , 251-252 (2002)
	*	Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <i>Nucleic Acids Research</i> 21:2867-2872 (1993)
	*	Genbank Accession No. AF020393
	*	Genbank Accession No. AF022375

EXAMINER 	DATE CONSIDERED 
--	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10/758,155

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

January 12, 2004

Group:

*	Genbank Accession No. AF024710
*	Genbank Accession No. AF035121
*	Genbank Accession No. AF063657
*	Genbank Accession No. AF063658
*	Genbank Accession No. AF092125
*	Genbank Accession No. AF092126
*	Genbank Accession No. AF092127
*	Genbank Accession No. AF095785
*	Genbank Accession No. AF098331
*	Genbank Accession No. AF437895
*	Genbank Accession No. AF468110
*	Genbank Accession No. AF486837
*	Genbank Accession No. AH006909
*	Genbank Accession No. AJ000185
*	Genbank Accession No. AJ010438
*	Genbank Accession No. AY047581
*	Genbank Accession No. D89630
*	Genbank Accession No. E13256
*	Genbank Accession No. E13332

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MCDONNELL BOEHMEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10/758,155

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

January 12, 2004

Group:

*	Genbank Accession No. E14000
*	Genbank Accession No. E14233
*	Genbank Accession No. E15156
*	Genbank Accession No. E15157
*	Genbank Accession No. NM_002019
*	Genbank Accession No. NM_002020
*	Genbank Accession No. NM_002253
*	Genbank Accession No. NM_003376
*	Genbank Accession No. NM_003377
*	Genbank Accession No. NM_004469
*	Genbank Accession No. NM_005429
*	Genbank Accession No. U01134
*	Genbank Accession No. X62568
*	Genbank Accession No. X94216
*	Genbank Accession No. Y08736
*	Godbey et al., "Poly(ethylenimine) and its role in gene delivery," <i>Journal of Controlled Release</i> , 60, 149-160 (1999)
*	Godbey et al., "Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery," <i>Proc. Natl. Acad. Sci. USA</i> , 96, 5177-5181 (1999)
*	Gold et al., "Diversity of Oligonucleotide Functions," <i>Annu. Rev. Biochem.</i> 64:763-797 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHLEN
MULBERRY & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10/758,155

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



Applicant:

McSwiggen et al.

Filing Date:

January 12, 2004

Group:

	*	Gonzalez et al., "New Class of Polymers for the Delivery of Macromolecular Therapeutics," Bioconjugate Chem. 10:1068-1074 (1999)
	*	Good et al., "Expression of small, therapeutic RNAs in human nuclei," Gene Therapy 4:45-54 (1997)
	*	Grant et al., "Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor," Diabetologia 36:282-291 (1993)
	*	Hall et al., "Establishment and Maintenance of a Heterochromatin Domain," Science 297:2232-2237 (2002)
	*	Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," Science, 286, 950-952 (1999)
	*	Hammond et al., "An RNA-Directed Nuclease Mediates Post-Transcriptional Gene Silencing in Drosophila Cells," Nature 404:293-296 (2000)
	*	Harborth et al., "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing," Antisense and Nucleic Acid Drug Development, 13:83-105 (2003)
	*	Hermann and Patel, "Adaptive Recognition by Nucleic Acid Aptamers," Science 287:820-825 (2000)
	*	Hofland and Huang, "Formulation and Delivery of Nucleic Acids," Handbook of Exp. Pharmacol. 137:165-192 (1999)
	*	Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods," VCH, 331-417 (1995)
	*	Hutvagner and Zamore, "A MicroRNA in a Multiple-Turnover RNAi Enzyme Complex," Science 297:2056-2060 (2002)
	*	Hutvagner et al., "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the let-7 Small Temporal RNA," Science 293:834-838 (2001)
	*	International Search Report for PCT/US03/05028 mailed October 17, 2003

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant:	
		McSwiggen et al.	
		Filing Date:	Group:
		January 12, 2004	


✓	•	International Search Report for PCT/US03/05346 mailed October 17, 2003
	•	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," Chem. Pharm. Bull. 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)
	•	Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," Science 229:345-352 (1985)
	•	Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," Tetrahedron Letters 34:301-304 (1993) (sometimes mistakenly referred to as Jsckhe)
	•	Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," Clinical Chemistry 45:1628-1650 (1999)
	•	Jenuwein, "An RNA-Guided Pathway for the Epigenome," Science 297:2215-2218 (2002)
	•	Jolliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," Fundam. Clin. Pharmacol. 13:16-26 (1999)
	•	Karle et al., "Differential Changes in Induced Seizures After Hippocampal Treatment of Rats with an Antisense Oligodeoxynucleotide to the GABA _A Receptor $\gamma 2$ Subunit," Euro. Jour. of Pharmacology 340:153-160 (1997)
	•	Karpeisky et al, "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," Tetrahedron Letters 39:1131-1134 (1998)
	•	Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," Antisense Research & Development 2:3-15 (1992)
	•	Kaspereit-Rittinghausen et al., "Animal Model of Human Disease: Hereditary Polycystic Kidney Disease," Amer. Jour. of Pathology 139:693-696 (1991)
✓	•	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," Nature 362:841-844 (1993)

EXAMINER		DATE CONSIDERED	2/15/06
----------	---	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: January 12, 2004	Group:

<input checked="" type="checkbox"/>	*	Koch et al., "Vascular Endothelial Growth Factor," Journal of Immunology 152:4149-4156 (1994)
<input type="checkbox"/>	*	Kusser, "Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution," Reviews in Molecular Biotechnology 74:27-38 (2000)
<input type="checkbox"/>	*	Kwak'et al., "VEGF Is Major Stimulator in Model of Choroidal Neovascularization," Investigative Ophthalmology & Visual Science, 41(10), 3158-3164 (2000)
<input type="checkbox"/>	*	Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," Chemical Reviews 95:2601-2627 (1995)
<input type="checkbox"/>	*	Lasic and Papahadjopoulos, "Liposomes Revisited," Science 267:1275-1276 (1995)
<input type="checkbox"/>	*	Lee and Larson, "Modified Liposome Formulations for Cytosolic Delivery of Macromolecules," ACS Symposium Series 752:184-192 (2000)
<input type="checkbox"/>	*	Lee and Lee, "Preparation of Cluster Glycosides of N-Acetylgalactosamine That Have Subnanomolar Binding Constants Towards the Mammalian Hepatic Gal/GalNAc-specific Receptor," Glyconjugates J. 4:317-328 (1987)
<input type="checkbox"/>	*	Lee et al., "Expression of Small Interfering RNA's Targeted Against HIV-1 rev Transcripts in Human Cells," Nature Biotechnology 19:500-505 (2002)
<input type="checkbox"/>	*	Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," <i>Biochemical and Biophysical Research Communications</i> , 295, 744-748 (2002)
<input type="checkbox"/>	*	Lepri et al., "Effect of Low Molecular Weight Heparan Sulphate on Angiogenesis in the Rat Cornea after Chemical Cauterization," Journal of Ocular Pharmacology 10:273-281 (1994)
<input type="checkbox"/>	*	L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α -Lactalbumin mRNA Levels in C1271 Mouse," EMBO J. 11:4411-4418 (1992)
<input checked="" type="checkbox"/>	*	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," Methods Enzymol. 217:47-66 (1993)

EXAMINER 	DATE CONSIDERED 2/15/06
---	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.


FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.	
(Use several sheets if necessary)		Filing Date: January 12, 2004	Group:

	*	Limbach et al., "Summary: the modified nucleosides of RNA," <i>Nucleic Acids Research</i> 22(12):2183-2196 (1994)
	*	Lin and Matteucci, "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acid," <i>J. Am. Chem. Soc.</i> 120:8531-8532 (1998)
	*	Lin et al., "A Novel mRNA-crRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)
	*	Lin et al., "Policing Rogue Genes", <i>Nature</i> 402:128-129 (1999)
	*	Liszewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:8000-8004 (1993)
	*	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <i>J. Biol. Chem.</i> 270(42):24864-24870 (1995)
	*	Loakes, "The Applications of Universal DNA Base Analogues," <i>Nucleic Acids Research</i> 29:2437-2447 (2001)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <i>Nucleic Acids Research</i> 21:2585-2589 (1993)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <i>Biochemistry</i> 32:1751-1758 (1993)
	*	Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <i>Cell</i> 110:563-574 (2002)
	*	Maurer et al., "Lipid-based systems for the intracellular delivery of genetic drugs," <i>Molecular Membrane Biology</i> 16:129-140 (1999)
	*	McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <i>Nucleosides & Nucleotides</i> 10:287-290 (1991)

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: January 12, 2004	Group:

* 	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," Proc. Natl. Acad. Sci. USA 83:399-403 (1986)
*	McLaren et al., "Vascular Endothelial Growth Factor (VEGF) Concentrations are Elevated in Peritoneal Fluid of Women with Endometriosis," Human Reproduction 11:220-223 (1996)
*	McLaren et al., "Vascular Endothelial Growth Factor is Produced by Peritoneal Fluid Macrophages in Endometriosis and Is Regulated by Ovarian Steroids," J. Clin. Invest. 98:482-489 (1996)
*	McManus et al., "Gene Silencing Using Micro-RNA Designed Hairpins," RNA 8:842-850 (2002)
*	Mesmaeker et al, "Novel Backbone Replacements for Oligonucleotides," American Chemical Society, pp. 24-39 (1994)
*	Millauer et al., "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant," Letters to Nature 367:576-579 (1994)
*	Miller et al., "Vascular Endothelial Growth Factor/Vascular Permeability Factor is Temporally and Spatially Correlated with Ocular Angiogenesis in a Primate Model," American Journal of Pathology 145:574-584 (1994)
*	Miyagishi and Taira, "U6 Promoter-driven siRNAs with Four Uridine 3' Overhangs Efficiently Suppress Targeted Gene Expression in Mammalian Cells," Nature Biotechnology 19:497-500 (2002)
*	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," Science 256:992-996 (1992)
*	Mori et al., "Inhibition of Choroidal Neovascularization by Intravenous Injection of Adenoviral Vectors Expressing Secreted Endostatin," American Journal of Pathology, 159(1), 313-320 (2001)
*	Mori et al., "Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization," Journal of Cellular Physiology, 118(2) 253-263 (2001)
* 	Noonberg et al., In vivo generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation," Nucleic Acids Research 22(14):2830-2836 (1994)

EXAMINER 	DATE CONSIDERED 2/15/06
---	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: January 12, 2004	Group:

*	Norby, "Angiogenesis: new aspects relating to its initiation and control," <i>APMIA</i> 105:417-437 (1997)
*	Novina et al., "siRNA-Directed Inhibition of HIV-1 Infection," <i>Nature Medicine</i> 1-6 (2002)
*	Nykanen et al., "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway," <i>Cell</i> 107:309-321 (2001)
*	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," <i>Nucleic Acids Symp. Ser.</i> 27:15-16 (1992)
*	Ohno-Matsui, et al., "Inducible Expression of Vascular Endothelial Growth Factor in Adult Mice Causes Severe Proliferative Retinopathy and Retinal Detachment," <i>Animal Models from the Departments of Ophthalmology and Neuroscience and Molecular Biology and Genetics, Am. J. Pathology</i> , 160, 711-719 (2002)
*	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <i>Proc. Natl. Acad. Sci. USA</i> 89:10802-10806 (1992)
*	Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <i>Biochimica et Biophysica Acta</i> 1238:86-90 (1995)
*	Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <i>Biochemistry</i> 30:9914-9921 (1991)
*	O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <i>Cell</i> 79:315-328 (1994)
*	Orgis et al., "DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression," <i>AAPS PharmSci.</i> , 3 (3) article 21 (http://www.pharmsci.org) p. 1- 11 (2001)
*	Ormerod et al., "Effects of Altering the Eicosanoid Precursor Pool on Neovascularization and Inflammation in the Alkali-burned Rabbit Cornea," <i>American Journal of Pathology</i> 137:1243-1252 (1990)
*	Pal-Bhadra et al., "Heterochromatic Silencing and HP1 Localization in <i>Drosophila</i> Are Dependent on the RNAi Machinery," <i>Science</i> , 303, 669-672 (2004)

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.




FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al. Filing Date: January 12, 2004	


* 	Pandey et al., "Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- α -Induced Angiogenesis," <i>Science</i> 268:567-569 (1995)
*	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo," <i>Proc. Natl. Acad. Sci. USA</i> 92:5592-5596 (1995)
*	Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <i>Molecular Cell</i> 6:1077-1087 (2000)
*	Passaniti et al., "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," <i>Laboratory Investigation</i> 67:519-528 (1992)
*	Paul et al., "Effective Expression of Small Interfering RNA in Human Cells," <i>Nature Biotechnology</i> 20:505-508 (2002)
*	Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," <i>Nature</i> 344:565-567 (1990) (often mistakenly listed as Perrault)
*	Petersen et al., "Polyethylenimine-graft-Poly(ethylene glycol) Copolymers: Influence of Copolymer Block Structure on DNA Complexation and Biological Activities as Gene Delivery System," <i>Bioconjugate Chem.</i> , 13, 845-854 (2002)
*	Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <i>Science</i> 253:314-317 (1991)
*	Pierce et al., "Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization," <i>Proc. Natl. Acad. Sci. USA</i> 92:905-909 (1995)
*	Plate, "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas in vivo," <i>Nature</i> 359:845-848 (1992)
* 	Ponpipom et al., "Cell-Specific Ligands for Selective Drug Delivery to Tissues and Organs," <i>J. Med. Chem.</i> 24:1388-1395 (1981)

EXAMINER 	DATE CONSIDERED 2/15/06
---	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.













FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al. Filing Date: January 12, 2004	

* 	Rajakumar et al., "Effects of Intrastriatal Infusion of D ₂ Receptor Antisense Oligonucleotide on Apomorphine-Induced Behaviors in the Rat," <i>Synapse</i> 26:199-208 (1997)
*	Reich et al., "Small Interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model," <i>Molecular Vision</i> , 9, 210-216 (2003)
*	Reinhart and Bartel, "Small RNAs Correspond to Centromer Heterochromatic Repeats," <i>Science</i> 297:1831 (2002)
*	Reinhart et al., "MicroRNAs in Plants," <i>Genes & Development</i> 16:1616-1626 (2002)
*	Reynolds et al., "Rational siRNA design for RNA interference," <i>Nature Biotechnology</i> , 22, 3, 326-330 (2004)
*	Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <i>J. Am. Chem. Soc.</i> 113:5109-5111 (1991)
*	Saenger (ed), "Modified Nucleosides and Nucleotides; Nucleoside Di- and Triphosphates; Coenzymes and Antibiotics, (ch.7)" <i>Principles of Nucleic Acid Structure</i> 158-200 (1984)
*	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" <i>Science</i> 247:1222-1225 (1990)
*	Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," <i>Proc. Natl. Acad. Sci. USA</i> 88:10591-10595 (1991)
*	Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using β -cyanoethyl protected ribonucleoside phosphoramidites," <i>Nucl Acids Res.</i> 18:5433-5441 (1990)
*	Schroeder et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," <i>Prog. Neuro-Psychopharmacol. & Biol. Psychiat.</i> 23:941-949 (1999) [sometimes cited by RPI as Prog Neuropsychopharmacol Biol Psychiatry 23:941-949, 1999]
* 	Schwarz et al., "Evidence that siRNAs Function as Guides, Not Primers, in the Drosophila and Human RNAi Pathways," <i>Molecular Cell</i> 10:537-548 (2002)
* 	Schwarz et al., "Asymmetry in the Assembly of the RNAi Enzyme Complex," <i>Cell</i> , 1115, 199-208 (2003)

EXAMINER 	DATE CONSIDERED 2/15/06
---	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant:	
		McSwiggen et al.	
		Filing Date:	Group:
		January 12, 2004	

* 	Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," <i>Nucleic Acids Research</i> 15:3113-3129 (1987)
* 	Senger et al., "Vascular permeability factor (VPF, VEGF) in tumor biology," <i>Cancer and Metastasis Reviews</i> 12:303-324 (1993)
* 	Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," <i>Nucleic Acids Research</i> 19:4247-4251 (1991)
* 	Sharp, Philip A., "RNAi and Double-strand RNA", <i>Genes and Development</i> 13:139-141 (1999)
* 	Sheehan et al., "Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides," <i>Nucleic Acids Research</i> , 31 (14), 4109-4118 (2003)
* 	Shifren et al., "Ovarian Steroid Regulation of Vascular Endothelial Growth Factor in the Human Endometrium: Implications for Angiogenesis during the Menstrual Cycle and in the Pathogenesis of Endometriosis," <i>The Journal of Clinical Endocrinology & Metabolism</i> 81:3112-3118 (1996)
* 	Shweiki et al., "Patterns of Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis," <i>J. Clin. Invest.</i> 91:2235-2243 (1993)
* 	Simantov et al., "Dopamine-Induced Apoptosis in Human Neuronal Cells: Inhibition by Nucleic Acids Antisense to the Dopamine Transporter," <i>Neuroscience</i> 74(1):39-50 (1996)
* 	Sommer et al., "The Spread and Uptake Pattern of Intracerebrally Administered Oligonucleotides in Nerve and Glial Cell Populations of the Rat Brain," <i>Antisense & Nucleic Acid Drug Development</i> 8:75-85 (1998)
* 	Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found" <i>Molecular Biology</i>, 286: 5441, p.886 (1999)
* 	Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," <i>Science</i> 262:1566-1569 (1993)
* 	Sun, "Technology evaluation: SELEX, Giliad Sciences Inc," <i>Current Opinion in Molecular Therapeutics</i> 2:100-105 (2000)

EXAMINER 	DATE CONSIDERED 2/15/06
--	-------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10758,155

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



Applicant:

McSwiggen et al.

Filing Date:

January 12, 2004

Group:

	Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both in vitro in place of run-off and (G)-free transcriptions and in vivo as multi-sequences transcription vectors," <i>Nucleic Acids Research</i> 19:5125-5130 (1991)
*	Takahashi et al., "Markedly Increased Amounts of Messenger RNAs for Vascular Endothelial Growth Factor and Placenta Growth Factor in Renal Cell Carcinoma Associated with Angiogenesis," <i>Cancer Research</i> 54:4233-4237 (1994)
*	Thomas et al., "Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells," <i>PNAS</i> , 99, 14640-14645 (2002)
*	Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter," <i>Nucleic Acids Research</i> 23:2259-2268 (1995)
*	Turner et al., "Improved Parameters for Prediction of RNA Structure," <i>Cold Spring Harbor Symposia on Quantitative Biology Volume LII</i> , pp. 123-133 (1987)
*	Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <i>J. Am. Chem. Soc.</i> 109:3783-3785 (1987)
*	Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," <i>Genes & Development</i> 13:3191-3197 (1999)
*	Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , 295, 3, 158-167 (2002)
*	Tuschl, "RNA Interference and Small Interfering RNAs," <i>Chembiochem</i> 2:239-245 (2001)
*	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <i>Proc. Natl. Acad. Sci. USA</i> 96:7053-7058 (1999)
	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <i>FEBS Letters</i> 421:280-284 (1998)
*	Uhlmann et al., "Studies on the Mechanism of Stabilization of Partially Phosphorothioated Oligonucleotides Against Nucleolytic Degradation," <i>Antisense & Nucleic Acid Drug Development</i> 7:345-350 (1997)

EXAMINER,

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
	Applicant: McSwiggen et al.	
	Filing Date: January 12, 2004	Group:

*	Ui-Tei et al., "Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference," Nucleic Acids Research, 32, 3, 936-948 (2004)
*	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," TIBS 17:334-339 (1992)
*	Usman and McSwiggen, "Ch. 30 - Catalytic RNA (Ribozymes) as Drugs," Annual Reports in Medicinal Chemistry 30:285-294 (1995)
*	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an Escherichia coli Formylmethionine tRNA," J. Am. Chem. Soc. 109:7845-7854 (1987)
*	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," Nucleic Acids Symposium Series 31:163-164 (1994)
*	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," Nucleic Acids Research 21:3249-3255 (1993)
*	Verdel et al., "RNAi-Mediated Targeting of Heterochromatin by the RITS Complex, Science, 303, 672-676 (2004)
*	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," Annu. Rev. Biochem. 67:99-134 (1998)
*	Volpe et al., "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi," Science 297:1833-1837 (2002)
*	Waterhouse, et al. "Virus Resistance and gene Silencing in Plants Can Be Induced by Simultaneous Expression of Sense and Antisense RNA" Proc. Natl. Acad. Sci. USA 99:13959-13964 (1998)
*	Weckbecker et al., "Intradermal angiogenesis in nude mice induced by human tumor cells or b-FGF," Angiogenesis Key Principles—Science—Technology—Medicine pp296-301 (1992)

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		McSwiggen et al.	
		Filing Date:	Group:
		January 12, 2004	

	*	Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4+ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," Journal of Virology 65:5531-5534 (1994)
	*	Wellstein and Czubayko, "Inhibition of Fibroblast Growth Factors," Breast Cancer Research and Treatment 38:109-119 (1996)
	*	Wianny and Zernicka-Goetz et al., "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development," Nature Cell Biology 2:70-75 (2000)
	*	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," Nucleic Acids Research 23(14):2677-2684 (1995)
	*	Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," Methods in Molecular Biology 74:59-69 (1997)
	*	Woo et al., "Taxol Inhibits Progression of Congenital Polycystic Kindey Disease," Nature 368:750-753 (1994)
	*	Wu and Wu, "Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System," The Journ. of Biol. Chem. 262:4429-4432 (1987)
	*	Wu et al., "Cardiac Defects and Renal Failure in Mice with Targeted Mutations in Pkd2," Nature Genetics 24:75-78 (2000)
	*	Wu-Pong et al., "Nucleic Acid Drug Delivery, Part 2; Delivery to the Brain," 32-38 (1999)
	*	Yamada et al., "Nanoparticles for the delivery of genes and drugs to human hepatocytes," Published online: 29 June 2003, doi:10.1038/nbt843 (August 2003 Volume 21 Number 8 pp 885-890) (2003)
	*	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993)
	*	Zamore et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," Cell 101:25-33 (2000)

EXAMINER	DATE CONSIDERED
	7/15/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-N
(400/142)

Serial No.

10/758,155

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



Applicant:


McSwiggen et al.

Filing Date:


January 12, 2004

Group:



	•	Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," Mol. Cell. Biol. 10:4529-4537 (1990)
	•	Ziche et al., "Angiogenesis Can Be Stimulated or Repressed In Vivo by a Change in GM3:GD3 Ganglioside Ratio," Laboratory Investigation 67:711-715 (1992)

EXAMINER 	DATE CONSIDERED 2/15/06
---	--------------------------------


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: January 12, 2004	Group:




U.S. PATENT APPLICATION DOCUMENTS


Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	US 2003/0190635	10/2003	McSwiggen et al.			
	*	US 2003/0206887	11/2003	Morrissey et al.			

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	6,346,398	02/12/02	Pavco et al.			


FOREIGN PATENT DOCUMENTS


		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	*	1325955	07/09/03	EP (Klippel-Giese et al.)				
	*	08208687	08/1996	JP (Hotoda et al.)				
	*	94/11499	05/26/94	WO (Ullrich et al.)				

EXAMINER 	DATE CONSIDERED 2/15/06
--	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
		Applicant: McSwiggen et al.	
		Filing Date: January 12, 2004	Group:

	*	94/21791	09/29/94	WO (Bergmann et al.)				
	*	95/04142	02/09/95	WO (Robinson)				
	*	95/13380	05/18/95	WO (Draper et al.)				
	*	97/00957	01/09/97	WO (Patterson-Winston et al.)				
	*	97/21808	06/19/97	WO (Robinson)				
	*	99/04819	02/04/99	WO (Klimuk et al.)				
	*	99/55857	11/04/99	WO (Beigelman et al.)				
	*	00/21560	04/20/00	WO (Alitalo et al.)				
	*	01/097850	12/27/01	WO (Siemeister et al.)				
	*	02/07747	01/31/02	WO (King)				
	*	02/10378	02/07/02	WO (Cowser et al.)				
	*	02/096927	12/05/02	WO (Escobedo et al.)				
	*	03/068797	08/21/03	WO (Rossi et al.)				
	*	03/070887	08/28/03	WO (McSwiggen et al.)				
	*	03/070896	08/28/03	WO (McSwiggen et al.)				
	*	03/070910	08/28/03	WO (McSwiggen et al.)				
	*	03/074654	09/12/03	WO (McSwiggen et al.)				
	*	03/080638	10/02/03	WO (Lacasse et al.)				
	*	04/009769	01/29/04	WO (Tolentino et al.)				

EXAMINER 	DATE CONSIDERED 2/16/06
--	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
		Applicant: McSwiggen et al.	
		Filing Date: January 12, 2004	Group:

	*	04/043977	05/27/04	WO (Prakush et al.)				
	*	04/072261	08/26/04	WO (Li et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc):

	*	Anderson et al., "Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance," <i>Oligonucleotides</i> , 13:303-312 (2003)
	*	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglyceryl derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984)
	*	Hasan et al., "VEGF antagonists," <i>Oncologic, Metabolic & Endocrine</i> , 703-718 (2001)
	*	International Search Report for PCT/US03/05022 mailed January 6, 2005
	*	International Search Report for PCT/US2004/016390 mailed March 31, 2005
	*	International Search Report for PCT/US2004/027403 mailed July 12, 2005
	*	International Search Report for PCT/US2004/030488 mailed January 12, 2005
	*	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> , 18:307-319 (2000)
	*	Kuwabara et al., "A C. elegans patched gene, ptc-1, functions in germ-line cytokinesis," <i>Genes and Development</i> , 14(15):1933-1944 (2000)
	*	Lu et al., "Tumor Inhibition By RNAi-Mediated VEGF an VEGFR2 Down Regulation in Xenograft Models," <i>Cancer Gene Therapy</i> , 10, Suppl. 1, S4-S5 (2003)
	*	Parry et al. 1999. "Bioactivity of anti-angiogenic ribozymes targeting <i>Flt-1</i> and <i>KDR</i> mRNA," <i>Nucleic Acid Res.</i> 27:2569-77
	*	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <i>Oncogene</i> 5:519-524 (1990)

EXAMINER 	DATE CONSIDERED 7/15/06
---------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.